Medtronic completes MiniMed spin-off, sharpening focus on high-growth cardiovascular and surgical businesses

What happened

Medtronic completed the separation of its diabetes business, MiniMed, which now trades independently as MMED on Nasdaq. This move removes approximately $2.8 billion in annual revenue (FY2025 diabetes segment) from Medtronic's consolidated results, leaving a more focused portfolio centered on cardiovascular, neuroscience, and medical surgical. The separation had been anticipated as part of activist-driven portfolio reshaping, following Elliott Management's engagement and board changes aimed at improving growth and profitability. While the spin-off may unlock shareholder value by allowing each entity to pursue tailored strategies, it also concentrates Medtronic's exposure to the competitive pulsed field ablation market, where Abbott's Volt launch is intensifying pressure. The transaction does not alter the near-term investment thesis, which remains contingent on PFA share gains, Hugo robotics commercialization, and resolution of the Applied litigation, but it removes a low-growth segment that had been a drag on overall margins.

Implication

The spin-off aligns with the activist-driven portfolio focus and may lead to a re-rating if the remaining Medtronic demonstrates higher growth and margin; however, it also removes a stable revenue stream and increases reliance on cardiovascular execution. The separation does not alter the pending litigation risk or competitive dynamics in PFA, which remain the key swing factors for the stock. Investors should monitor FY26 Q4 results for PFA share momentum and commentary on pricing as Abbott's Volt ramps, as well as any updated guidance from management on the post-spin financial profile. If the stock reacts positively to the spin-off and approaches or exceeds the $105 trim level indicated in our prior analysis, disciplined investors should consider trimming rather than chasing. Conversely, a pullback toward the $90 attractive entry level could present an opportunity if the core growth drivers remain intact.

Thesis delta

The MiniMed separation is consistent with the portfolio-focus narrative, but it does not alter the central investment question of whether PFA share gains are sustainable. We maintain our WAIT rating, though we would revisit entry/trim levels if the remaining Medtronic trades at a materially different multiple post-spin-off. The removal of diabetes may improve blended margins and growth, but it also increases concentration risk in cardiovascular, which remains the primary driver of the investment case.